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Abstract
5-aza-29-deoxycytidine (5-aza-CdR) is used extensively as a demethylating agent and acts in concert with histone
deacetylase inhibitors (HDACI) to induce apoptosis or inhibition of cell proliferation in human cancer cells. Whether the
action of 5-aza-CdR in this synergistic effect results from demethylation by this agent is not yet clear. In this study we found
that inhibition of cell proliferation was not observed when cells with knockdown of DNA methyltransferase 1 (DNMT1), or
double knock down of DNMT1-DNMT3A or DNMT1-DNMT3B were treated with HDACI, implying that the demethylating
function of 5-aza-CdR may be not involved in this synergistic effect. Further study showed that there was a causal
relationship between 5-aza-CdR induced DNA damage and the amount of [
3H]-5-aza-CdR incorporated in DNA. However,
incorporated [
3H]-5-aza-CdR gradually decreased when cells were incubated in [
3H]-5-aza-CdR free medium, indicating that
5-aza-CdR, which is an abnormal base, may be excluded by the cell repair system. It was of interest that HDACI significantly
postponed the removal of the incorporated [
3H]-5-aza-CdR from DNA. Moreover, HDAC inhibitor showed selective synergy
with nucleoside analog-induced DNA damage to inhibit cell proliferation, but showed no such effect with other DNA
damage stresses such as c-ray and UV, etoposide or cisplatin. This study demonstrates that HDACI synergistically inhibits cell
proliferation with nucleoside analogs by suppressing removal of incorporated harmful nucleotide analogs from DNA.
Citation: Chai G, Li L, Zhou W, Wu L, Zhao Y, et al. (2008) HDAC Inhibitors Act with 5-aza-29-Deoxycytidine to Inhibit Cell Proliferation by Suppressing Removal of
Incorporated Abases in Lung Cancer Cells. PLoS ONE 3(6): e2445. doi:10.1371/journal.pone.0002445
Editor: Dong-Yan Jin, University of Hong Kong, China
Received March 15, 2008; Accepted May 12, 2008; Published June 18, 2008
Copyright:  2008 Chai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study is supported by National Natural Science Foundation of China (No.30425017, 30670417 and 30621002), and grants (2005CB522403,
2006AA02Z101, 2006CB910300 and B07001) from the Ministry of Science and Technology of China.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: zhuweiguo@bjmu.edu.cn
. These authors contributed equally to this work.
Introduction
It is well known that DNA methylation is associated with histone
acetylation status in regulation of gene expression [1–4] or cell
proliferation and aging [5]. This linkage between histone status
and DNA methylation was well confirmed by Cameron et al who
found that several genes silenced by methylation were reactivated
when treated with demethylating agent 5-aza-CdR and histone
deacetylase inhibitor (HDACI) trichostatin A (TSA) together, but
were not reactivated in the presence of 5-aza-CdR or TSA alone
[6]. Later, several laboratories including our own extended these
findings to set up a therapeutic strategy for cancer treatment, in
which 5-aza-CdR acts in conjunction with depsipeptide/TSA to
induce significant apoptotic cell death [7–10]. Since DNA
methylation in the promoter region is associated with HDAC1
by a methyl-binding protein MeCP2 [11], it is believable that
certain genes, if hypermethylated in their promoter region, are
more tightly packed by histones and thus transcription factors
access their DNA binding sites only with greater difficulty.
Consequently, cell death related genes, which are silenced due
to hypermethylation, could be reactivated by treatment with 5-
aza-CdR; this reactivation should be strengthened by HDACI,
and at the same time, cell death should be more readily observable
as well.
However, 5-aza-CdR also plays an anti-neoplastic role which is
methylation-independent [12–14]. 5-aza-CdR may act directly on
mitochondria and induce apoptosis in mammalian cells [14]. A
direct methylation independent evidence for the 5-aza-CdR
induced cell death is that 5-aza-CdR significantly enhances
expression of Apaf-1 or p19
INK4d to induce cell death, however
the promoter regions of these genes are totally unmethylated
[12,13]. 5-aza-CdR has also been reported to induce a synergistic
effect by increasing the cisplatin bound to DNA, via a change in
the topology of DNA brought about by 5-aza-CdR without its
functioning as a demethylating agent [15]. These data suggest that
5-aza-CdR plays diverse roles in cells which include both
demethylating functions and methylation-independent functions.
The cytotoxicity of 5-aza-CdR results from its capacity to
damage DNA as 5-aza-CdR is a nucleoside analog (NA) and can
be incorporated into the DNA backbone [16,17], which in turn
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2445may induce formation of a covalent adduct between the 5-aza-
CdR molecule and methyltranferases [16]. It has been demon-
strated that NAs such as 5-aza-CdR or cytarabine (Ara-C), are
phosphorylated into their triphosphate form and are then
incorporated into DNA during replication [18]. Subsequently,
the incorporated NA serve as an abase that may induce DNA
damage, mutations and stalling of the DNA replication fork
[19,20]. These changes in the DNA backbone are harmful, and
DNA damage sensors such as DNA-PK, p53, ATM and ATR
recognize these damaged sites and repair the abnormal DNA
[21,22]. Previously, both our group and other researchers directly
confirmed that 5-aza-CdR induces DNA damage and elicits p53-
dependent biological reactions [23–25]. However, if the abnormal
DNA changes induced by the incorporation of NAs are
overwhelmed, or the DNA repair systems are severely inhibited,
the cells will undergo apoptosis [26].
HDAC inhibitors are novel and effective anticancer agents
[27,28], which are involved in regulating many genes including
activation of p53 [29], or downregulating anti-apoptotic genes
[28,30] to exert an anti-neoplastic effect. Therefore, investigation
of whether or not HDACI also affects DNA repair enzymes to
enhance NA-induced DNA damage is called for.
In this study, we confirm that 5-aza-CdR acts in concert with
HDACI to induce a significant inhibition of cell proliferation in a
methylation independent manner. 5-aza-CdR was incorporated
into DNA in a dose and time dependent manner that was clearly
associated with induction of DNA single-strand breaks (SSB) by 5-
aza-CdR. HDAC inhibitors significantly suppressed removal of
the incorporated 5-aza-CdR from DNA and thus produced a
synergistic effect resulting in inhibition of cell proliferation
Materials and Methods
Cell culture and chemical treatment
Human lung cancer cell lines A549 and H719 were used in this
study. Both 5-aza-CdR (dissolved in 50% acetic acid) and Ara-C
(dissolved in DMSO) (both purchased from Sigma, St Louis, MO)
were added fresh into the medium every 24 hrs. TSA (Sigma) was
dissolved in ethanol. Depsipeptide (kindly provided by the NIH)
was dissolved in DMSO.
Determination of cell proliferation by MTT assay
Equal numbers of cells (approximately 5000/well) were seeded
into a 96-well plate 24 hrs prior to experimentation. Cells were
treated with 5-aza-CdR, Ara-C, c-irradiation and HDACI alone
or in combination. After treatment, MTT dye solution (Sigma)
was added into the 96-well plate. The corrected absorbance of
each sample was calculated by comparison with the untreated
control.
RT-PCR
To determine if knockdown of DNA methyltransferases
(DNMTs) is effective in DNA demethylating and reactivating
silenced genes, RT-PCR was performed to detect changes in
expression of p21 that is silenced due to a hypermethylation in the
p21 promoter [31]. The PCR primers were as follows: p21, left
primer- GGA AGA CCA TGT GGA CCT GT and right primer-
GGA TTA GGG CTT CCT CTT GG; b-actin, left primer-
TGG AGA AGA GCT ACG AGC TGC CTG and right primer-
GTG CCG CCA GAC AGC ACT GTG TTG.
Western Blot
To identify changes in protein expression in cells treated with
knockdown of DNMTs or 5-aza-CdR, cells were harvested with a
scraper and then washed once with cold phosphate-buffered saline.
The cells were then lysed in lysis buffer (50 mM Tris-HCl, 250 mM
NaCl, 5 mM EDTA, 50 mM NaF, 0.15% Igepal CA-630, and
1.5 mM phenylmethylsulfonyl fluoride). Equal amounts of proteins
(100–150 mg) were size fractionated on 7.5–12.5% SDS-PAGE. In
addition, to determine the amount of the chromatin-bound RPA,
cells were lysed in solution A (50 mM Tris-HCl, pH 7.8, 420 mM
NaCl, 1 mM EDTA, 0.5% NP-40, 0.34 M sucrose, 10% glycerol,
1m MN a 3VO4 and protease inhibitor cocktail). To obtain nuclear
extracts, cells were lysed in buffer B (10 mM HEPES, pH 7.9,
10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 0.1%
Triton X-100, protease inhibitor cocktail). Isolated nuclei were
washed once with buffer B and further lysed in buffer A as above.
To obtain chromatin-bound proteins, isolated nuclei were lysed in
buffer C (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT) and further
lysed in buffer A as above.
The antibodies used were anti-PARP (Santa Cruz, F-2), anti-
RPA (Santa Cruz, MA34 and MA70-2), anti-c-H2AX (Upstate,
05-636), anti-DNMT1(Santa Cruz, H-300), anti-DNMT3A (Santa
Cruz, P-16), anti-DNMT3B (a gift from Dr. Xu, G, Shanghai
Institute of Biological Science) and b-actin antibodies were
purchased from Santa Cruz.
DNA bisulfite treatment and bisulfite sequencing
To evaluate changes in DNA methylation status after treatment
with knockdown of DNMTs, DNA was treated with sodium
bisulfite and purified for PCR as described previously [31]. The
primers for sequencing the p21 promoter were as follows: left
primer, 59-GGG AGG AGG GAA GTG TTT TT -39 and right
primer, 59-ACA ACT ACT CAC ACC TCA ACT-39. The PCR
products were gel extracted (Qiagen, Valencia, CA) and ligated
into a pGEM-T easy vector, by using the TA cloning system
(Promega, Madison, WI). Transformed bacteria DH5a were
cultured overnight, and the plasmid DNA was isolated using a kit
(Qiagen). At least 10 separate clones were chosen for sequence
analysis.
Comet assay
The comet assay was performed as described previously [24]. In
brief, frosted microscopic slides were covered with 0.5% normal
melting agarose at 60uC. About 10
5 5-aza-CdR treated or
untreated cells in PBS were mixed with an equal amount of 1%
low melting agarose to form a cell suspension. After electropho-
resis, slides were examined at 6006 magnification and pictures
were taken with a fluorescence microscope (TCS, Leica,
Manheim, Germany).
Analysis of exclusion of incorporated [
3H]-5-aza-CdR from
DNA
The radiolabeled nucleoside analog incorporation assay was
performed as described previously with modifications [32]. [
3H]-5-
aza-CdR was purchased from Moravek Biochemicals (MT1676, 1
mCi/ml, Brea, CA). H719 and A549 cells were treated with [
3H]-
5-aza-CdR at 1 mM for 48 hrs with or without depsipeptide at
0.1 mM for the final 6 hrs (from 42 to 48 hrs) and the cells were
then washed with cold PBS. The cells were then replaced in [
3H]-
5-aza-CdR free medium and incubated for 6, 12 or 24 hrs. Cold
trichloroacetic acid (TCA, 50%) was then added to the cell
solution and the TCA-insoluble DNA was placed on a glass
microfiber filter (Whatman, Maidstone, England). This glass filter
with TCA-insoluble DNA was placed in a vial to count
radioactivity with a Beckman LS 5000 Liquid Scintillation
Counter.
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clone
The pCMVneo -DNMT1 antisense plasmid was kindly
provided by Dr. SB Baylin [33]. The vector was transfected into
H719 cells using the Qiagen Effectene Transfection kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions.
Twenty-four hrs after the first transfection, a second transfection
was performed to strengthen the efficiency of the RNAi, and then
800 mg/ml of G418 was added to select stable cells with DNMT1
antisense.
RNA interfering with DNMT3A, DNMT3B
The RNAi targeted oligonucleotide sequences are as follows:
CAT CCA CTG TGA ATG ATA ATT (DNMT3A) and GAT
Figure 1. Suppression of DNA methyltransferases is sufficient to induce demethylation. (A) Representative Western blot indicates that
DNMT1 protein level in H719 cells was significantly decreased in the DNMT1-deficient stable clone when compared to the non-specific
oligonucleotide treated control. (B) and (C) Representative Western blots also show that DNMT3A or DNMT3B protein level was significantly
decreased after RNAi treatment in DKD of DNMT1/DNMT3A cells or DKD of DNMT1/DNMT3B cells, respectively. b-actin is shown as a loading control
in the lower panel. (D) A schematic diagram showing the p21
Waf1/Cip1 promoter, with the black region indicating the fragment which underwent
bisulfite sequencing (2233 to +2 relative to transcription start site). (E) With bisulfite sequencing, 10 clones were randomly selected and the
methylation status of the p21
Waf1/Cip1 promoter was determined in untreated H719 cells or in the H719 cells treated with knockdown of DNMT1, DKD
of DNMT1/DNMT3A or DKD of DNMT1/DNMT3B. (F) RNA was extracted from H719 cells treated with DKD of DNMT1/DNMT3B, and RT-PCR was
performed to detect expression of p21 mRNA. b-actin is shown as a loading control for the RT-PCR analysis.
doi:10.1371/journal.pone.0002445.g001
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Shanghai GeneChem Company). The oligonucleotides for
DNMT3A and DNMT3B siRNA were transfected into cells by
using lipofectamine 2000 for 48 hrs.
Results
5-aza-29-deoxycytidine cooperates with HDACI to induce
inhibition of cell proliferation by a methylation
independent mechanism
It has been reported that 5-aza-CdR acts together with HDAC
inhibitors to synergistically induce cell death or inhibition of cell
proliferation [7–10]. To investigate whether the role of 5-aza-CdR
involved in this synergistic inhibition of cell proliferation when
combined with HDACI is epigenetic, two double knock down
(DKD) clones (DKD of DNMT1/DNMT3A and DKD of
DNMT1/DNMT3B) were established. To avoid inducing a
difference in efficiency of transfection when cells were transfected
with two vectors or two RNAi oligonucleotides, a DNMT1
deficient stable clone was first established by transfection of a
vector with antisense DNMT1 cDNA into H719 cells and selected
with G418. As shown in Fig. 1A, DNMT1 protein is well knocked
down in this stable H719 cell line. Thereafter, DKD of DNMT1/
DNMT3A, or DNMT1/DNMT3B was carried out by transfec-
tion of DNMT3A or DNMT3B RNA oligonucleotides into the
DNMT1 knockdown stable cells. Figure 1B–C shows clearly that
DNMT3A and DNMT3B protein levels were significantly
reduced by these RNAi treatments. To evaluate whether these
DKDs of DNMTs were efficient for demethylating DNA, the
methylation status of the p21
Waf1/Cip1 promoter was chosen for
testing with bisulfite sequencing because the p21
Waf1/Cip1 promoter
is highly methylated in H719 cells [31]. Fig. 1D represents a
schematic diagram showing the promoter region of p21
Waf1/
Cip1and the fragment designated for bisulfite sequencing. As shown
in Fig. 1E, the p21
Waf1/Cip1 promoter in H719 cells was highly
methylated (51.25% of CGs in the p21
Waf1/Cip1 promoter were
methylated in 10 selected clones). However, methylated CGs were
decreased to 23.75%, 21.5% and 12.5% when
DNMT1,DNMT1/DNMT3A and DNMT1/DNMT3B were
subjected to double knock down with 10 selected clones (Fig. 1E),
indicating that knockdown of DNMT1 and DNMT3B together
was the most efficient for DNA demethylation. This decrease in
methylation of the p21
Waf1/Cip1 promoter was clearly associated
with expression of p21 as measured with RT-PCR (Fig. 1F).
An unexpected finding was that we did not observe a difference
in cell proliferation when H719 cells with DKDs or TKDs
(knockdown of DNMT1/3A/3B) were treated with or without
depsipeptide and assayed with MTT (Fig. 2A). In contrast, cell
proliferation was significantly decreased in both A549 and H719
cells which were treated with 5-aza-CdR and HDACI depsipep-
tide/TSA, although 5-aza-CdR alone and depsipeptide/TSA
alone had little effect on inhibition of cell proliferation at the doses
used (Fig. 2B–C). However, 5-aza-CdR-induced inhibition of cell
proliferation was cell line dependent. For example, 5-aza-CdR
showed an obvious effect in inhibiting proliferation of A549 cells
(Fig. 2C), but had no effect in H719 cells (Fig. 2B). These
differences in the 5-aza-CdR-induced effect on cell proliferation
between A549 and H719 cells resulted from the p53 status of the
treated cells [24]. A549 cells have a wild-type p53, whereas H719
cell p53 is mutated [31]. In addition, although procaine has been
reported to be a demethylating agent [34], synergistic inhibition of
cell proliferation was not observed when H719 cells were treated
with procaine (0.5 mM for 72 hrs) and depsipeptide (0.1 mM for
6 hrs at 66–72 hrs) or TSA (1 mM for 6 hrs at 66–72 hrs) (Fig. 2D).
These data suggest that the role of 5-aza-CdR in its synergistic
effect with HDACI in inducing inhibition of cell proliferation may
not result from its demethylating function.
5-aza-CdR induces cytotoxicity by incorporation into
DNA as a nucleoside analog
It is well known that 5-aza-CdR is phosphorylated to its
triphosphate form in cells and then incorporated into DNA during
replication [18]. In order to investigate the degree of 5-aza-CdR
incorporation into cells, [
3H]-5-aza-CdR was added to A549 or
H719 cells for 24 hrs and DNA was then extracted with TCA
precipitation. Radioactivity per mg DNA was measured. As shown
in Fig. 3A–B, incorporation of [
3H]-5-aza-CdR into DNA was
concentration dependent in both cell lines. Incorporated radioac-
tivity per mg DNA at 0.1 mM and 1 mMo f[
3H]-5-aza-CdR
increased ,2- and ,12-fold respectively in H719 cells, and ,10-
and ,110-fold respectively in A549 cells when compared to the
radioactivity of 0.01 mM[
3H]-5-aza-CdR in both cell lines.
There was a relationship between incorporated 5-aza-CdR and
DNA damage as determined with the comet assay. Figure 3C–E
shows that 5-aza-CdR exhibited a dose-dependent capacity for
DNA damage in A549 cells, which was demonstrated by presence
of a DNA tail. Larger DNA tail area and longer DNA tail length
represent greater DNA damage. Table 1 shows a statistic analysis
of the comet assay comparing 5-aza-CdR treated samples to an
untreated control. This data parallels the incorporated amount of
5-aza-CdR, and implies that 5-aza-CdR plays a role in cytotoxicity
by incorporation into DNA.
As apoptosis can also give a positive result in the comet assay
[35], we harvested 5-aza-CdR treated cells and performed flow
cytometry analysis to determine whether 5-aza-CdR-induced
DNA damage elicits apoptotic cell death. The cells with DNA
content smaller than that of G0/G1 (region of M1 in figure 4) are
considered to be apoptotic cells. As shown in Fig. 4, 5-aza-CdR
did not induce apoptosis in A549 cells at 0.1 mM (Fig. 4B) or 1 mM
for 72 hrs (Fig. 4C). In addition, A549 cells were treated with 5-
aza-CdR at 1 mM for 48 hrs or 72 hrsand protein was extracted
for Western blotting using anti-PARP (cleavage of PARP is a
hallmark of apoptosis). Fig. 4D shows that 5-aza-CdR did not
induce apoptotic cell death at limited doses. These data indicate
that 5-aza-CdR alone at limited doses is not able to induce
apoptosis and thus the positive result in the comet assay results
mainly from 5-aza-CdR induced DNA damage.
In general, DNA damaging agents induce DNA single-strand
breaks (SSB) or double-strand breaks (DSB). To determine which
kind of DNA damage is induced by 5-aza-CdR, we performed
Western blotting using anti-RPA (replication protein A) or c-
H2AX. Most DNA damaging agents induce cellular responses
Figure 2. HDAC inhibitor depsipeptide or TSA and knockdown of DNMTs do not cooperate to inhibit cell proliferation. (A) H719 cells
with deficient DNMT1, DKD of DNMT1/DNMT3A, DKD of DNMT1/DNMT3B, or TKD (triple knockdown) of DNMT1/DNMT3A/DNMT3B were treated with
or without depsipeptide at 0.1 mM for 6 hrs, and cell proliferation was tested with the MTT assay. (B) and (C) 5-aza-CdR (1 mM for 72 hrs) cooperates
with HDAC inhibitor depsipeptide (0.1 mM for the final 6 hrs) or TSA (1 mM for the final 6 hrs) to synergistically induce inhibition of cell proliferation in
H719 (B) or A549 cells (C). (D) H719 cells were treated with procaine (0.5 mM) for 72 hrs, and depsipeptide (0.1 mM for the final 6 hrs) or TSA (1 mM for
the final 6 hrs) was then added to the treated cells. All data are the results of two separate experiments.
doi:10.1371/journal.pone.0002445.g002
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the activation of ATR is largely dependent on an intermediate
molecule RPA [41,42]. Chromatin was extracted from 5-aza-CdR
treated H719 cells and chromatin-bound RPA content was
determined. Fig. 5A shows that chromatin-bound RPA was
increased in response to increased 5-aza-CdR, indicating that 5-
aza-CdR induced DNA damage may be single-strand breaks
(SSB). On the other hand, c-H2AX is considered to be a hallmark
of DNA double-strand breaks (DSB) [43], and Western blotting
was therefore performed using ant-c-H2AX to rule out the
possibility of 5-aza-CdR induced DSB. Fig. 5B shows that 5-aza-
CdR at 1 m did not induce DSB. However, 5-aza-CdR at higher
concentration (.5 mM) induced dose-dependent DSB (data not
shown). These data demonstrate that 5-aza-CdR induced DNA
SSB or DSB is dosage dependent. In this study, 5-aza-CdR was
almost always used at lower doses (1 mM) and thus the 5-aza-CdR
induced DNA damage is SSB.
Depsipeptide specifically inhibits removal of
incorporated 5-aza-CdR and enhances nucleoside analog
induced cytotoxicity
Because DNA damage induced by low dose of 5-aza-CdR is
reversible, it is particularly important to understand how HDAC
inhibitor enhances 5-aza-CdR-induced toxicity. In addition, as
sequential treatment of 5-aza-CdR and HDAC inhibitor is more
effective in inducing cell death [44], we were led to consider
whether HDACI increases uptake of 5-aza-CdR into DNA or
Figure 3. The amount of [
3H]-5-aza-CdR incorporated into DNA parallels the degree of 5-aza-CdR induced DNA damage. (A) H719 or
(B) A549 cells were incubated with [
3H]-5-aza-CdR for 24 hrs at different concentrations and then washed with cold PBS. The cells were incubated in
fresh medium for another 24 hrs, and DNA was then precipitated with cold TCA. Radioactivity was measured and relative radioactivity per mg was
counted. Same amount of DNA was loaded and run at 1% of agarose gel at 100 V for 5 min as loading control, which is shown at upper panel of
Fig. 3A and Fig. 3B, respectively. The results presented are from two separate experiments (mean6SD) DNA damage induced by 5-aza-CdR in H719
cells was determined by the comet assay. (C) Untreated control, (D) 5-aza-CdR at 0.1 mM for 72 hrs and (E) 5-aza-CdR at 1 mM for 72 hrs.
doi:10.1371/journal.pone.0002445.g003
Table 1. DNA damage induced by 5-aza-CdR was detected
with the comet assay.
Treatment Tail area/Total area ( % ) DNA tail length
0 mM 11.3684 . 1 60.2
0.1 mM 35.8611 7.7560.8
1 mM 52.866 15.560.6
With fluorescence microscope analysis software, the percentage of the DNA tail
area was divided to total DNA area for each A549 cell, and percentage of DNA
tail length divided to total DNA length are counted. The data represent an
average from 50 cells with standard error.
doi:10.1371/journal.pone.0002445.t001
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enhancing 5-aza-CdR-induced cytotoxicity. First, depsipeptide
(0.1 mM) and [
3H]-5-aza-CdR (1 mM) were added together to
A549 cells for an initial 6 hrs, and the cells were then continuously
cultured in medium with [
3H]-5-aza-CdR alone for another
42 hrs. Radioactivity was counted at 0–24 hrs after cells were
incubated in a radioactivity-free medium. By comparing samples
treated with [
3H]-5-aza-CdR alone to samples treated with [
3H]-
5-aza-CdR plus depsipeptide, no difference in radioactivity was
observed, indicating that depsipeptide does not promote incorpo-
ration of [
3H]-5-aza-CdR into DNA (Fig. 6A). To test whether
depsipeptide affects removal of incorporated 5-aza-CdR, a decay
analysis of incorporated [
3H]-5-aza-CdR was carried out in A549
cells. Cells were treated with [
3H]-5-aza-CdR at 1 mM for 48 hrs,
with and without depsipeptide at 0.1 mM for the final 6 hrs of
treatment, and the cells were then washed and replaced in fresh
medium (without experimental reagents) for 6, 12 and 24 hrs.
Figure 6A shows that incorporated [
3H]-5-aza-CdR gradually
decreased during incubation in [
3H]-5-aza-CdR free medium.
Radioactivity per mg DNA at 6, 12 and 24 hrs in cells treated with
[
3H]-5-aza-CdR alone, for example, was decreased to
78.4467.08%, 57.563.88% and 36.0561.79% respectively,
compared to the radioactivity at the beginning of incubation.
This reflects removal of [
3H]-5-aza-CdR from DNA. However,
addition of depsipeptide significantly postponed the removal of
[
3H]-5-aza-CdR from DNA, and radioactivity per mg DNA at 6,
12 and 24 hrs was 80.3613.21%, 78.71612.72% and
82.5620.47%, respectively, compared to the radioactivity at the
beginning of incubation. This depsipeptide induced decrease in
removal of [
3H]-5-aza-CdR was also dependent on depsipeptide
concentration. For example, the radioactivity of cells treated with
[
3H]-5-aza-CdR and depsipeptide at 0.05 mM, 0.1 mM and
0.2 mM showed 1.8-, 2.7- and 3.25 -fold increases respectively
over that of cells treated with [
3H]-5-aza-CdR alone (Fig. 6B). In
addition, 5-aza-CdR induced DNA damage also gradually
recovered when cells were cultured in a 5-aza-CdR free medium.
The length and area of the DNA tail induced by 5-aza-CdR were
shorter and smaller when cells were cultured in 5-aza-CdR free
medium for 12 hrs as compared to the cells without drug-free
incubation (Fig. 6C–E). This process of recovery from 5-aza-CdR
induced DNA damage was significantly suppressed by depsipep-
tide, so that the length and area of the tails in the comet assay were
longer and larger when cells were treated with 5-aza-CdR and
depsipeptide together (Fig. 6F–H). The depsipeptide-induced
suppression of recovery from 5-aza-CdR induced DNA damage
is summarized in table 2. These data suggest that HDAC inhibitor
may suppress recovery from 5-aza-CdR induced DNA damage
and synergistically induce inhibition of cell proliferation.
HDAC inhibitor acted selectively with nucleotide analog
to induce inhibition of cell proliferation
To determine whether HDACI selectively enhances NA-
induced cytotoxicity, H719 cells were treated with Ara-C, another
cytidine analog, and depsipeptide or TSA was then added to the
cells to observe changes in cell proliferation assayed with MTT. It
was of interest that both depsipeptide and TSA significantly
Figure 4. 5-aza-CdR at limited dose does not induce apoptosis. (A–C) To determine whether 5-aza-CdR-induced DNA damage induces
inhibition of cell proliferation via apoptotic cell death, a flow cytometry analysis was performed. Untreated A549 cells (A) or A549 cells were treated
with 5-aza-CdR at 0.1 mM (B) or at 1 mM for 72 hrs (C), and the cells were then harvested for staining with Propidium Iodide (PI). DNA content with
smaller than G0/G1 was considered as apoptotic DNA (area of M1). (D) A549 cells were treated with 5-aza-CdR at 1 mM for 48 or 72 hrs and protein
was extracted for Western blotting using anti-PARP to detect PARP cleavage in cells treated with 5-aza-CdR. An apoptotic positive control was shown
at the lane of the far right, in which there are two bands indicating the PARP (116 KD) and PARP cleavaged (85 KD).
doi:10.1371/journal.pone.0002445.g004
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B). However, this synergistic inhibition of cell proliferation was not
observed in the cells treated with depsipeptide and other DNA
damage inducers such as c-ray (Fig. 7C), UV (Fig. 7D), cisplatin
(Fig. 7E) or etoposide (Fig. 7F). These data suggest that HDACI
selectively acts in concert with NAs to induce inhibition of cell
proliferation.
Discussion
It is clear that 5-aza-CdR is a potent demethylating agent, in
that 5-aza-CdR is readily incorporated into DNA, and the
nitrogen substitution for the 5-carbon in the cytosine moiety is
able to confer the ability to trap DNA methyltransferase 1
[16,28,45]. In theory, inhibition of both DNA methylation and
HDAC will increase expression of genes if they are methylated in
their promoter regions, because methyl-binding proteins specifi-
cally bind to methylated DNA and recruit HDAC activity [11,46].
In fact, the effectiveness of this combination in treatment of cancer
is the subject of a number of human clinical trials by several
different groups [7,8,47,48]. There are reports indicating that
methylation in the promoter region of caspase 8 or caspase 1 is one
reason that cells develop resistance to chemotherapy [49,50], and
treatment with 5-aza-CdR could help abolish this resistance and
restore chemotherapy induced cell death [49,51]. However, in
most cases of 5-aza-CdR induced apoptosis, it is generally unclear
which gene or pathway leads to this effect. We tested the
methylation status of several important apoptotic related genes
including p53, bcl-2, bax and caspase 8, but all of these were
hypomethylated in the cells tested (data not shown). In addition, in
the present study, although DNMT1/DNMT3A/DNMT3B were
effectively knocked down (Fig. 1A–C), depsipeptide was not able to
induce a synergistic inhibition of cell proliferation (Fig. 2A).
Therefore, the synergistic effects of 5-aza-CdR in combination
with HDACI in inhibition of cell proliferation most likely have an
alternative mechanism that is methylation-independent.
In addition to its demethylating function, 5-aza-CdR also has
anti-neoplastic activity which operates by damaging DNA
[24,25,52]. Most NAs exert their cytotoxicity through interference
with DNA replication. It has been found experimentally that NAs
incorporated into DNA and abases inhibit template function and
chain elongation [26]. In addition, the incorporated abases
competitively inhibit DNA polymerase a in opposition to the
normal substrate deoxycytidine 59-triphosphate [53]. The NAs
also cause an unusual reiteration of DNA segments, which results
in multiple copies of limited portions of DNA and increases the
possibility of recombination, crossover, gaps and breaks [54]. 5-
aza-CdR differs from physiological cytidine by the presence of a
nitrogen at the 5- position of the heterocyclic ring and this
substitution renders the ring chemically unstable and leads to
spontaneous decomposition of its compounds in neutral solution
[26]. The incorporated 5-aza-CdR or its unstable form which has
a ring that breaks open inducing DNA damage, consequently may
elicit many different cellular responses using different pathways to
repair the resultant DNA damage. Consistent with these reports,
our data demonstrate that 5-aza-CdR can induce DNA damage in
a dose-dependent manner (Fig. 3C–E), and the degree of DNA
damage induced by 5-aza-CdR also parallels the amount of
incorporated [3H]-5-aza-CdR (Fig. 3A–B compares to Fig. 3C–E).
Here it should be pointed out that 5-aza-CdR induced DNA
damage is a SSB at lower doses as demonstrated by an increase in
chromatin-bound RPA, and absence of formation of c-H2AX
(Fig. 5A–B). However, when 5-aza-CdR was used at a higher
concentration (for example, .5 mM), formation of c-H2AX was
observed in response to 5-aza-CdR treatment (data not shown).
We propose that 5-aza-CdR is randomly incorporated into DNA
as a cytosine substitution, and thus higher concentrations of 5-aza-
Figure 5. 5-aza-CdR induces DNA damage with a single-strand
break (SSB). (A–B) H719 cells were treated with 5-aza-CdR (0.1–1 mM)
for 48 h, and cellular extracts including the chromatin fraction (A, Chr)
and soluble fraction (B, Sol) were isolated for Western blotting to detect
changes in RPA70 and RPA32. The band intensity of untreated sample
was set as 1. The numerical value of each sample represents the
percentage of band intensity relative to that of untreated sample. (C)
H719 cells were also treated with 5-aza-CdR at 1 mM for 24, 48 or 72 hrs,
and protein was then extracted for Western blotting using anti-c-H2AX.
Cells were treated with doxorubicin at 1 mM for 24 hrs as a positive
control (far right lane).
doi:10.1371/journal.pone.0002445.g005
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PLoS ONE | www.plosone.org 8 June 2008 | Volume 3 | Issue 6 | e2445Figure 6. Depsipeptide inhibits removal of incorporated 5-aza-CdR from DNA. (A) H719 cells were incubated with [
3H]-5-aza-CdR for
48 hrs, with presence or absence of depsipeptide at 0.1 mM for the first 6 hrs (depsipeptide+[
3H]-5-aza-CdR) or last 6 hrs ([
3H]-5-aza-
CdR+depsipeptide) and then washed with cold PBS. The cells were replaced in fresh medium for further incubation for different intervals and the
DNA was then extracted with cold TCA. Relative radioactivity of each sample at different time points was compared to the radioactivity of the cells at
the beginning of the incubation. (B) H719 cells were treated with [
3H]-5-aza-CdR for 48 hrs, and depsipeptide at 0.05, 0.1 and 0.2 mM was then added
to the cells for the last 6 hrs. At 24 hrs after incubation, cells were harvested and radioactivity was counted. Same amount of DNA was loaded and run
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the other hand, as single-strand breaks can be turn into DSBs if the
replication fork is interrupted [55,56], the possibility of co-
existence of SSB and DSB is reasonable, and it may be dependent
of dosage and degree of DNA damage.
However, cells have a capacity to exclude harmful abases and
repair DNA damage induced by different stimuli. A chief
difference from radiation- or other stimuli-induced DNA damage
is that NA induced DNA damage usually is limited to an alteration
in a DNA base or a nucleotide. The enzymes that are responsible
for excision of incorporated 5-aza-CdR or Ara-C have not been
clearly identified. However, more than 10 distinct DNA
glycosylases have been found in cells which can repair abase-
induced DNA damage, including enzymes specific for excision of
uracil or 5-methyl-uracil [57]. There are two classes of enzymes
for base excision repair: ‘‘short patch’’ involved enzymes and
‘‘long patch’’ involved enzymes [58]. The base excision repair
(BER) initiated by enzymes for the ‘‘short patch’’ are glycosylases
that include UNG, TDG, SMUG1 and MBD4. For example,
uracil represents an endogenous DNA lesion that results from
deamination of cytosine or incorporation of uracil instead of T
during replication [59]. As a uracil DNA glycosylase, UNG, has
been considered to be a key enzyme for removal of uracil in DNA
[60]. However, although UNG is highly selective for uracil in
DNA, it also removes certain bases that are structurally related to
cytosine. These related bases include 5-fluorouracil in DNA
[61,62], 5-hydroxy-29-deoxyuridine [63,64] and alloxan [64]. In
E. coli, for example, mutation of uracil DNA glycosylase leads to a
50-fold increase of 5-fluorouracil incorporated into DNA [65]. In
human lymphoblasts, UNG was also found to remove 5-
fluorouracil in vitro [61]. As early as 1980s, it was reported that
5-aza-CdR induced DNA damage results from a single-strand
break and glycosylase recognizes and removes 5-aza-CdR from
DNA [66]. In this study, we analyzed expression of enzymes that
are mainly responsible for BER in depsipeptide treated cells, and
only UNG expression was obviously inhibited (data not shown).
However, UNG may be not directly involved in excising the 5-aza-
CdR adduct since RNAi against UNG is not sufficient to mimic
the effect of depsipeptide in its synergistic effect in inhibiting cell
proliferation with 5-aza-CdR (data not shown). We also tested to
see whether depsipeptide influences activities of enzymes for ‘‘long
patch repair’’ including human apurinic/apyrimidinic endonucle-
ase 1 (APE1) and flap endonuclease 1 (FEN1). However,
depsipeptide did not inhibit expression of APE1 and FEN1 (data
not shown). These data reflect the complexity of 5-aza-CdR
induced DNA damage and the enzymes involved in repairing the
damaged DNA.
5-aza-CdR-induced DNA damage was previously reported to
come from a bulky adduct of 5-aza-CdR and DNMT1 [16]. This
adduct may be excised by several enzymes that are involved in
nucleotide excision repair (NER) [58]. Therefore, identification of
enzymes which operate in NER is a critical step for the future.
HDAC inhibitors seem likely to be specific in their synergy with
NAs to induce inhibition of cell proliferation, since no inhibition of
cell proliferation after treatment with depsipeptide in cells
irradiated with c-rays or treated with other DNA damage inducers
was observed (Fig. 7C–F). In support of this, HDAC inhibitor MS-
275 interacts synergistically with different nucleoside analogs, but
not with other DNA damaging agents to induce apoptosis in
different human cancer cells [48]. These data suggest that HDACI
may specifically suppress expression or activity of enzymes that are
involved in repairing nucleoside analog-induced DNA damage.
Therefore, to identify which enzyme(s) is responsible for repairing
NA incorporation, understanding of cytosine analog-induced
DNA damage is extremely critical and may be useful for designing
new therapeutic strategies to treat cancer.
In conclusion, in this study we demonstrate that 5-aza-CdR
exerts cytotoxicity by incorporating into DNA and inducing DNA
damage. HDACI may interfere with the repair process of
nucleoside analog induced DNA damage, and thus lead to a
Table 2. Recovery from 5-aza-CdR-induced DNA damage and inhibition of recovery by depsipeptide were analyzed with the
comet assay
Treatment Tail area/Total area ( % ) DNA tail length
CTR 6.662 2.260.2
Depsipeptide 6 hr 6.962 2.360.2
5-aza-CdR 24 hr 40.2642 6 . 2 62.0
5-aza-CdR 24 hr+incubation 12 hr 26.664 9.861.4
5-aza-CdR 24 hr+incubation 24 hr 14.862 4.861.2
5-aza-CdR+depsipeptide 24 hr 45.4662 7 . 9 63.2
5-aza-CdR+depsipeptide 24 hr+incubation 12 hr 53.4664 0 . 2 63.4
5-aza-CdR+depsipeptide 24 hr+incubation 24 hr 72.2614 70.1610.3
A549 cells were treated with 5-aza-CdR (1 mM for 24 hrs), depsipeptide (0.1 mM for 6 hrs) alone or with both drugs in combination. The treated cells were immediately
assayed with comet assay or washed and further incubated in a drug-free medium for 24 hrs and then assayed with comet assay.
doi:10.1371/journal.pone.0002445.t002
at 1% of agarose gel at 100 V for 5 min as loading control, which is shown at upper panel of Fig. 6A and Fig. 6B, respectively. (C–E) Comet assay
shows that 5-aza-CdR induced DNA damage recovered when the treated cells were incubated in 5-aza-CdR free medium for 12 hrs. (C) Untreated
control, (D) 5-aza-CdR at 1 mM for 24 hrs without incubation, and (E) 5-aza-CdR at 1 mM for 24 hrs, followed by washing for further incubation in a
drug-free medium for 12 hrs. (F–H) Recovery of DNA damage induced by 5-aza-CdR was inhibited by depsipeptide treatment (0.1 mM for the final
6 hrs). (F) Depsipeptide treated cells (0.1 mM) for 6 hrs, (G) Cells were treated with 5-aza-CdR (1 mM for 24 hr) and depsipeptide (0.1 mM for last
6 hrs) without incubation, or (H) Cells treated as above and further incubated in a drug-free medium for 12 hrs.
doi:10.1371/journal.pone.0002445.g006
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PLoS ONE | www.plosone.org 10 June 2008 | Volume 3 | Issue 6 | e2445Figure 7. HDAC inhibitors selectively cooperated with nucleoside analog to synergistically induce inhibition of cell proliferation.
(A) H719 cells or (B) A549 cells were treated with Ara-C at 0.1 mM for 72 hrs in the presence or absence of HDACI (depsipeptide 0.1 mM or TSA 2 mM
for the final 6 hrs). The cells were then washed and further incubated for 24 hrs for MTT assay. (C) Effect of interaction of HDACI and irradiation at 2
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novel finding will be helpful in formulating a new strategy to treat
cancer more effectively in the clinic.
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